Background
Nitric oxide plays an important role in the biological functions of many cell types within the heart. [1] [2] [3] The molecule is formed enzymatically from l-arginine through the action of the enzyme nitric oxide synthase (NOS). NOS exists in several isoforms, including constitutive isoforms which are present in endothelial cells (eNOS) and some nerves (nNOS). These two isoforms of the enzyme require the presence of extracellular calcium for the binding of calmodulin. [4] [5] [6] In addition, an inducible isoform of the enzyme (iNOS) is expressed in vitro and in vivo following administration of certain cytokines and/or lipopolysaccharide (LPS). 1, 7 In contrast to constitutive isoforms, iNOS is able to bind calmodulin at very low levels of extracellular free calcium. [8] [9] [10] It is now known that nitric oxide plays an important role in cardiac function. 11 Nitric oxide can exert a negative inotropic effect in cultured guinea pig myocytes, an effect augmented by enhanced nitric oxide production induced by endotoxin. 12 In addition, nitric oxide can also affect diastolic function by quickening ventricular relaxation and enhancing chamber passive relaxation. [13] [14] [15] The actions of nitric oxide on the coronary circulation have been well studied. Endothelium-dependent relaxation has been shown to be mediated by the release of nitric oxide in human coronary arteries. 16 This release is mediated by the eNOS isoform of the enzyme and occurs in response to pharmacological stimulation, mechanical stimuli such as shear stress and via a continuous basal release. 1 Nitric oxide release by the coronary vascular endothelium has four principal actions which regulate the function of the vessel wall: (1) relaxation of vascular smooth muscle; (2) inhibition of platelet adherence and aggregation; (3) regulation of cellular attachment and migration of blood elements into the vessel wall, and (4) regulation of the cell cycle, resulting in the inhibition of vascular smooth muscle cell growth. Alterations in the function and expression of eNOS can thus have profound effects on the function of the vessel wall. Indeed, reductions in nitric Correspondence: Dr AH Chester oxide release have been shown to play a role in structural and functional changes in the coronary circulation that are seen in atherosclerosis and restenosis after angioplasty. 17 Recent evidence has suggested a possible role for nitric oxide in mediating some of the changes observed in the function and structure of the heart after transplantation. These include a role for iNOS in mediating rejection and heart failure, [18] [19] [20] [21] [22] [23] endothelial dysfunction due to inhibition of eNOS in the coronary circulation and cyclosporin-induced endothelial toxicity, 24, 25 as well as a possible major role in post-transplant coronary arterial disease.
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Role of iNOS in transplantation
iNOS expression can occur in macrophages, lymphocytes, smooth muscle cells, endothelial cells and myocytes. 22, 23, 30, 31 Expression in any of these cells could play an important role in rejection. Furthermore CD4 lymphocytes may differentiate into Th1 or Th2 cells which differ in cytokine secretion patterns and immunological effector functions. Nitric oxide may modulate T cell differentiation into Th1 or Th2 or alter the functions of these differentiated T cells. 27 The Th1 and Th2-type cytokines may in turn themselves regulate nitric oxide production.
Acute rejection
Animal studies suggest that iNOS is expressed in acute cardiac allograft rejection. 18, 22 Expression of iNOS has been detected during both early and late acute rejection. 32 Both mRNA and protein for iNOS have been observed in ventricular homogenates and isolated rat cardiac myocytes from rejecting allografts, but not from syngeneic control grafts. 22 These authors also used immunocytochemistry to show iNOS expression in infiltrating macrophages, microvascular endothelial cells and cardiac myocytes from rejecting grafts. The iNOS enzyme and mRNA has also been localised to infiltrating inflammatory cells in rejecting grafts in the rat. 18 Aminoguanidine, a preferential inhibitor of the iNOS isoform, prevents increased nitric oxide production, significantly reduces the histologic grade of rejection and prolongs graft survival. 18 L-N G -monomethyl-l-arginine (L-NMMA), which blocks both constitutive and inducible NOS isoforms, also produces a small increase in graft survival. 33 Nitrate and nitrite are the end products of nitric oxide breakdown in the blood and are an index of nitric oxide production. 34, 35 Two rat cardiac allograft studies have shown increased plasma nitrate and nitrite during the early stages of rejection. 18, 36 Urinary nitrate excretion has also been shown to increase eight-fold in untreated rejection compared to that seen in isografts. 37 Only three studies have been performed in human allografts, with contradictory results. One showed serum nitrate to be significantly increased in acute rejection and that serum nitrate concentration correlated closely with the grade of rejection. 38 Another study found that urinary nitrate was significantly elevated in a subgroup of patients during acute rejection, although overall there was only a trend towards increased nitrate with moderate or severe rejection. 39 The third study showed that iNOS mRNA was detected in every patient at some time after transplantation, but its expression was not related to the histological grade of rejection and was no different in those with, than in those without rejection. 40 Furthermore, serum nitrate levels did not correlate with iNOS mRNA expression.
Immunosuppressive drugs are given in an attempt to prevent acute rejection. These may have the capacity to interfere with the production of nitric oxide. Cyclosporin and FK506 have been shown to suppress serum nitrate and nitrite. 41, 42 A significant reduction in iNOS mRNA and enzyme activity has been observed in cardiac myocytes after treatment with FK506, cyclosporin, dexamethasone or a combination of all three, 42 and greater than 99% inhibition of induction of iNOS mRNA has been shown with dexamethasone treatment. 43 
Myocardial dysfunction during acute rejection
During acute rejection episodes, myocardial dysfunction commonly occurs, which causes morbidity and occasionally mortality. [44] [45] [46] The dysfunction is predominantly diastolic, 46 and does not always correlate with the grade of morphological rejection seen in the biopsy. 47 Nitric oxide may cause myocardial dysfunction during acute rejection. One study found a significant association between iNOS expression and both systolic and diastolic left ventricular dysfunction. 40 Furthermore, a rat cardiac allograft study has shown that aminoguanidine inhibits nitric oxide production and prevents allograft contractile and electrophysiological dysfunction. 48 In addition, aminoguanidine has been shown to significantly reduce cGMP levels and enhance shortening of allograft myocytes. 49 Hence iNOS expression may occur in acute rejection and the subsequent nitric oxide production may result in contractile dysfunction.
Role of iNOS in transplant coronary disease
Transplant coronary artery disease is a major problem late after transplantation and recent evidence suggests iNOS may play a role in its development. iNOS expression has been detected in the arteries of transplant patients with coronary disease, 28, 29 where it was seen in neointimal macrophages and smooth muscle cells. Inhibition of iNOS in a rat model of transplantation resulted in increased intimal thickening of the coronary arteries. 26 In addition, in transplanted iNOS-deficient mice there is increased luminal occlusion compared to normal mice. 27 Immunostaining for iNOS showed that it was localised to both infiltrating recipient macrophages and donor parenchymal cells (myocytes, smooth muscle cells and endothelial cells) in allografts from wildtype recipients, whereas in allografts from iNOSdeficient recipients, iNOS was absent in graft-infiltrating inflammatory cells and present only within donor parenchymal cells. These studies appear to suggest that the enhanced production of nitric oxide in these models of transplantation, is having a protective effect against the development of transplant coronary disease.
eNOS following cardiac transplantation
Cardiac transplantation exposes the coronary arterial circulation to a number of factors that may initiate injury to the endothelium and initiate graft vasculopathy. Such factors include the effect of preservation solutions, peri-operative hypoxia, acute and chronic rejection, cyclosporin toxicity and viral infections. 50, 51 These factors then become superimposed upon those pre-existing risk factors carried by patients prior to their transplants.
Endothelial perturbation can trigger a wide range of structural and functional changes in the endothelium. One possible regulatory mechanism that is believed to be affected, and may contribute to the onset of graft vasculopathy, is the function of eNOS. Damage to the endothelium in this way will deprive the vessel wall of the vasodilator action, anti-proliferative effects and regulation of cellular adhesion that is offered by endothelial-derived nitric oxide.
The function of the endothelium has been widely studied in transplant recipients. 24, [52] [53] [54] [55] [56] The response of the coronary arteries to intra-coronary injection of acetylcholine has been shown to change from dilation in normal coronary vessels to either no response or a vasoconstriction in transplanted hearts. 24 In contrast, the response to substance P in coronary arteries from transplanted hearts that were angiographically normal, is similar to that observed in non-transplanted hearts. 53 However, the response of both substance P and acetylcholine is attenuated in the vessels of hearts that are affected by graft vasculopathy. 24, 54, 55 This inhibition of the effect of nitric oxide is also apparent in angiographically normal coronary segments in hearts with atherosclerotic changes in other regions of the coronary circulation. 54 This dysfunction of the endothelium has also been shown to occur in non-cardiac vessels. Responses to acetylcholine in the internal mammary artery are also attenuated in patients who had been transplanted for idiopathic dilated cardiomyopathy. 57 The precise mechanisms and level at which damage to the nitric oxide pathway occurs in endo-thelial cells following transplantation is unclear. There is evidence to suggest that the production of nitric oxide may be governed by the availability of the precursor for nitric oxide formation, l-arginine. Impaired responses to acetylcholine can be restored by intra-coronary infusion of l-arginine in the coronary and peripheral circulation. 52 l-arginine can also enhance cardiac preservation via augmentation of the nitric oxide pathway.
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Cyclosporin-induced endothelial toxicity
The mechanisms of cyclosporin-induced toxicity are unclear. It is known that patients receiving this drug may develop systemic hypertension, nephrotoxicity and increased rates of thromboembolic events. [59] [60] [61] Effects of cyclosporin on the sympathetic nervous system, disruption in the balance between prostaglandin-thromboxane production, enhanced release of endothelin and increases in cytosolic calcium concentration have all been suggested as possible mechanisms that mediate the unwanted side effects of this drug. 62 An effect of cyclosporin on the release of nitric oxide from the vascular endothelium has also been implicated to contribute to the cause of these symptoms. It has been shown that in a number of different vascular beds and isolated blood vessels, cyclosporin can cause reductions in the degree of endothelium-dependent relaxation. [63] [64] [65] [66] [67] In addition, in vivo studies using two-dimensional and Doppler ultrasound showed that acute administration of cyclosporin impaired the dilator effect of acetylcholine. 63 This effect was independent of the vehicle used to dissolve the drug, or an increase in circulating levels of endothelin. However, it has been shown that cremophor EL, the vehicle for cyclosporin, can itself cause endothelial dysfunction in the isolated rat heart, an effect aggravated by cyclosporin. 68 In contrast, there have been studies that have looked at the affect of cyclosporin on the reactivity of the coronary endothelium in human blood vessels. 69, 70 Only at concentrations as high as 2000 ng/ml was any degree of endothelial dysfunction evident in isolated segments of human epicardial coronary arteries. 69 Concentrations in the range of 100-1000 ng/ml showed no inhibitory effect on the relaxation responses induced by the endothelium-dependent vasodilator substance P. Similar responses could also be obtained in arteries removed from the hearts of patients who were receiving a second transplant. These vessels had therefore been exposed to clinical concentrations of cyclosporin in a transplanted environment for between 2 days and 37 months. Irrespective of the duration of the transplant the vessels were still capable of relaxing to substance P. These results were complemented in the same study by intra-coronary injection of substance P into the hearts of transplant recipients. Substance P achieved a similar degree of relaxation as that obtained with a maximal concentration of isosorbide dinitrate. There was no observable correlation between the degree of relaxation achieved with substance P or isosorbide dinitrate with the blood concentration of cyclosporin in the individual patients. Recent evidence suggests that acute exposure to cyclosporin in healthy subjects can result in an enhancement of both basal and stimulated release of nitric oxide. 71 These data in human coronary arteries strongly suggest that cyclosporin does not inhibit nitric oxide release from the coronary endothelium. However, these studies are compared to those in animals, which have used acetylcholine as an endotheliumdependent probe. The possibility exists that either there is a species difference in the sensitivity of the vascular endothelium to the effects of cyclosporin, or that acetylcholine is a more sensitive probe in detecting subtle changes in the activity of eNOS. Even if the coronary endothelium is resistant to the toxic effects of cyclosporin, this does not preclude the possibility that endothelial cells in the renal vasculature or those in the systemic circulation may respond in a different fashion. Indeed, it has been shown that relaxation of human subcutaneous resistance vessels is inhibited by cyclosporin.
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Future directions
There is now strong evidence that the l-argininenitric oxide pathway undergoes several changes and that these changes can play a major role in clinical outcome. Further studies are required to fully understand the role and relevance of damage or activation of the l-arginine-nitric oxide pathway following cardiac transplantation. In some situations, diminished amounts of nitric oxide appear to be deleterious, while in others over-production may be equally damaging. Such studies need to define the precise mechanisms responsible for changes in the expression and activity of the different NOS enzymes, and ultimately how these changes may therefore be avoided. This may then open additional therapeutic targets and more effective pharmacological management of heart transplant patients.
